临床肿瘤学杂志

参考文献

[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.

[2]World Health Organization.Health statistics and information systems:WHO mortality database[EB/OL].2014[2015-08-10].http://who.int/healthinfo/mortality_data/en/.

[3]中国肿瘤登记中心.2015年中国肿瘤登记年报[EB/OL].2015[2015-08-10].http://www.huaxia.com/sp/xwss/dlxw/2015/04/4355225.html.

[4]中华医学会消化内镜学分会,中国抗癌协会肿瘤内镜学专业委员会.中国早期胃癌筛查及内镜诊治共识意见[J].胃肠病学,2014,19(7):408-427.

[5]国家卫生部.胃癌诊疗规范(2011年版)[EB/OL].2011-02-16[2015-08-10].http://www.nhfpc.gov.cn/yzygj/s3585u/201103/96ce9016858d416f83da688df45e3f2e.shtml.

[6]National Comprehensive Cancer Network,Inc.NCCN clinical practice guidelines in oncology:Gastric cancer(Version2.2015)[EB/OL].2015[2015-08-10].http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.

[7]Li J,Qin S,Xu J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phaseⅡtrial[J].J Clin Oncol,2013,31(26):3219-3225.

[8]Qin SK.PhaseⅢstudy of Apatinib in advanced gastric cancer:A randomized,double-blind,placebo-controlled trial[C].J Clin Oncol,2014,32(15 Suppl):a4003.

[9]缪建华,束永前.肿瘤内科相关事件临床处理策略[M].南京:东南大学出版社,2015:368-398.

[10]Mariette H,Joep H,Stefan S,et al.Cardiovascular and renal toxicity during angiogenesis inhibition:clinical and mechanistic aspects[J].J Hypertens,2009,27(12):2297-2309.

[11]Rini BI.Biomarkers:Hypertension following anti-angiogenesis therapy[J].Clin Adv Hematol Oncol,2010,8(6):415-416.

[12]Kostas N,Eleni K,Paraskevi B,et al.Bevacizumab-induced hypertension pathogenesis and management[J].Bio Drugs,2011,25(3):159-169.

[13]Roodhart JM,Langenberg MH,Witteveen E,et al.The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway[J].Curr Clin Pharmacol,2008,3(2):132-143.

[14]Eremina V,Jefferson JA,Kowalewska J,et al.VEGF inhibition and renal thrombotic microangiopathy[J].N Engl J Med,2008,358(11):1129-1136.

[15]Lankhorst S,Kappers MH,van Esch JH,et al.Hypertension during vascular endothelial growth factor inhibition:focus on nitric oxide,endothelin-1,and oxidative stress[J].Antioxid Redox Signal,2014,20(1):135-145.

[16]Maitland ML,Bakris GL,Black HR,et al.Initial assessment,surveillance,and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors[J].J Natl Cancer Inst,2010,102(9):596-604.

[17]Ivanyi P,Winkler T,Ganser A,et al.Novel therapies in advanced renal cell carcinoma:Management of adverse events from sorafenib and sunitinib[J].Dtsch Arztebl Int,2008,105(13):232-237.

[18]Larochelle P,Kollmannsberger C,Feldman R,et al.Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents[J].Curr Oncol,2012,19(4):202

[19]Cohen RB,Oudard S.Antiangiogenic therapy for advanced renal cell carcinoma:management of treatment-related toxicities[J].Invest New Drugs,2012,30(5):2066-2079.

[20]中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-741.

[21]中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.老年高血压的诊断与治疗中国专家共识(2011版)[J].中国医学前沿杂志,2012,4(2):31-39.

[22]贾守微,刘韬,黄红兵.分子靶向抗肿瘤药物的不良反应及其处理对策[J].肿瘤药学,2014,34(1):2-9.

[23]方勇,刘丽莉.分子靶向药物的不良反应及处理方法[J/OL].临床肿瘤学论坛,2015[2015-08-10].http://cancer.cmt.com.cn/detail/746299.html.

[24]Zhu X,Wu S,Dahut WL,et al.Risks of proteinuria and hypertension with bevacizumab,an antibody against vascular endothelial growth factor:systematic review and metaanalysis[J].Am J Kidney Dis,2007,9(2):186-193.

[25]刘巍,王龙,刘端祺.靶向药物不良反应的认识与思考[J].医学与哲学(临床决策论坛版),2011,32(2):19-24.

[26]Eremina V,Baelde HJ,Quaggin SE.Role of the VEGF--a signaling pathway in the glomerulus:evidence for crosstalk between components of the lomerular filtration barrier[J].Nephron Physiol,2007,106(2):32-37.

[27]National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification[J].Am J Kidney Dis,2002,39(2 Suppl 1):1-266.

[28]Amin C,Wallen E,Pruthi RS,et al.Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy[J].Urology,2008,72(4):864-868.

[29]刘淑英,王晓稼.贝伐单抗在肿瘤治疗中相关毒副反应[J].肿瘤学杂志,2009,15(12):1133-1135.

[30]Ren Z,Zhu K,Kang H,et al.Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma[J].J Clin Oncol,2015,33(8):894-900.

[31]Mc Lellan B,Kerr H.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib[J].Dermatol Ther,2011,24(4):396-400.

[32]国虹,刘卫东,董桂兰,等.分子靶向药物索拉非尼不良反应的防治[J].中国临床医生,2010,38(5):33-34.

[33]Zuo RC,Apolo AB,Di Giovanna JJ,et al.Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib[J].JAMA Dermatol,2015,151(2):170-177.

[34]Porta C,Paglino C,Imarisio I,et al.Uncovering pandora'svase:the growing problem of new toxicities from novel anticancer agents.The case of sorafenib and sunitinib[J].Clin Exp Med,2007,7(4):127-134.

[35]Manchen E,Robert C,Porta C.Management of tyrosine kinase inhibitor-induced hand-foot skin reaction:viewpoints from the medical oncologist,dermatologist,and oncology nurse[J].J Support Oncol,2011,9(1):13-23.

[36]Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356(2):125-134.

[37]Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferonalfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,356(2):115-124.

[38]Bollèe G,Patey N,Cazajous G,et al.Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib[J].Nephrol Dial Transplant,2009,24(2):682-685.

[39]Kane RC,Farrell AT,Saber H,et al.Sorafenib for the treatment of advanced renal cell carcinoma[J].Clin Cancer Res,2006,12(24):7271-7278.

[40]礼来公司.注射用Cyramza(雷莫芦单抗[ramucirumab])使用说明书2014年4月第一版[EB/OL].2014-04-21[2015-08-20].http://blog.sina.cn/dpool/blog/s/blog_5948305d0101l-70r.html?vt=4.